Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Autologous human fibroblasts - Fibrocell Science; Azfibrocel-T; azficel-T fibroblast suspension; Fibroblast cell therapy - Fibrocell Science; Isolagen therapy; Laviv

Latest Information Update: 19 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isolagen
  • Developer Fibrocell Science
  • Class Cell therapies; Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Dysphonia; Periodontal disorders; Scars

Highest Development Phases

  • Marketed Facial wrinkles
  • Discontinued Dysphonia; Periodontal disorders; Scars

Most Recent Events

  • 16 Dec 2019 Fibrocell Science has been acquired by Castle Creek Pharmaceuticals
  • 21 Dec 2016 Fibrocell Science completes a phase II trial for Dysphonia in USA (Injection) (NCT02120781)
  • 07 Jul 2016 Fibrocell Technologies terminates phase II trial in Scars (Restrictive burn scars) in USA (NCT01858753)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top